|
|
Volumn 5, Issue 6, 2014, Pages 410-
|
|
Current hypotheses of lithium's mechanism of action as a neuropsychiatric medication
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ARACHIDONIC ACID;
CARBAMAZEPINE;
FLUORODEOXYGLUCOSE F 18;
GLUCOSE;
GLYCOGEN SYNTHASE KINASE 3BETA;
INOSITOL;
INOSITOL MONOPHOSPHATASE;
LAMOTRIGINE;
LITHIUM;
MAMMALIAN TARGET OF RAPAMYCIN;
MOOD STABILIZER;
PHOSPHATASE;
UNCLASSIFIED DRUG;
VALPROIC ACID;
LITHIUM DERIVATIVE;
NEUROPROTECTIVE AGENT;
PSYCHOTROPIC AGENT;
ANTIINFLAMMATORY ACTIVITY;
AUTOPHAGY;
BIPOLAR DISORDER;
BRAIN DEGENERATION;
BRAIN METABOLISM;
CENTRAL NERVOUS SYSTEM;
CEREBELLUM;
DRUG EFFICACY;
DRUG MECHANISM;
EDITORIAL;
ENZYME INHIBITION;
FRAGILE X SYNDROME;
GLUCOSE METABOLISM;
HIPPOCAMPUS;
HUMAN;
MOOD DISORDER;
NEUROPROTECTION;
NEUROPSYCHIATRY;
NONHUMAN;
PHENOTYPE;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
PSYCHOPHARMACOTHERAPY;
TRAUMATIC BRAIN INJURY;
TREATMENT RESPONSE;
ANIMAL;
ANIMALS;
HUMANS;
LITHIUM COMPOUNDS;
NEUROPROTECTIVE AGENTS;
PSYCHOTROPIC DRUGS;
|
|
EID: 84902657014
PISSN: None
EISSN: 19487193
Source Type: Journal
DOI: 10.1021/cn5001183 Document Type: Editorial |
|
Times cited : (3)
|
|
References (0)
|
